| Not Yet Recruiting | Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age Wit NCT06534502 | Azurity Pharmaceuticals | Phase 4 |
| Recruiting | High-resolution Multi-parametric Magnetic Resonance Imaging for Focal Epilepsy NCT06550726 | Chinese University of Hong Kong | N/A |
| Recruiting | A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures NCT06967012 | Affiliated Hospital of Nantong University | Phase 4 |
| Not Yet Recruiting | Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy NCT06374966 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures NCT06590896 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Effects of Diazepam on RNS Detections NCT05273398 | University of Cincinnati | Phase 4 |
| Active Not Recruiting | Thermocoagulation in Drug Resistant Focal Epilepsy NCT05248269 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | N/A |
| Completed | Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies NCT05015868 | IRCCS Eugenio Medea | N/A |
| Active Not Recruiting | Transcranial Direct Current to Treat Epilepsy at Home NCT04309812 | Stanford University | N/A |
| Completed | Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW NCT03689114 | Mario Negri Institute for Pharmacological Research | Phase 4 |
| Recruiting | Treating Postictal Symptoms Using Ibuprofen and Nifedipine NCT03949478 | University of Calgary | Phase 2 |
| Unknown | Novel Network Analysis of Intracranial Stereoelectroencephalography NCT03916848 | Great Ormond Street Hospital for Children NHS Foundation Trust | N/A |
| Unknown | Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractor NCT03882151 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Completed | Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study NCT03446664 | LivaNova | N/A |
| Completed | Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study NCT03054961 | Medical College of Wisconsin | — |
| Terminated | Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of- NCT02635633 | University Hospital, Ghent | N/A |
| Completed | Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy NCT03200769 | University Hospital, Lille | N/A |
| Completed | Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS) NCT01745952 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Completed | Brain P-gp and Inflammation in People With Epilepsy NCT01663545 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Completed | Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan) NCT01441401 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | — |
| Completed | Once-A-Day Pregabalin For Partial Seizures NCT01262677 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Completed | Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug NCT01098162 | UCB Pharma GmbH | — |
| Completed | Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epileps NCT00918047 | Supernus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures NCT00772603 | Supernus Pharmaceuticals, Inc. | Phase 3 |
| Completed | Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onse NCT00771927 | UCB Pharma | — |
| Completed | A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With NCT00620555 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Withdrawn | A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Se NCT00422110 | UCB Pharma | Phase 2 / Phase 3 |
| Completed | Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures NCT00537940 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Completed | A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial S NCT00603473 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Terminated | Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures NCT00524030 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Completed | Drug Use Investigation Of Gabapentin NCT00567268 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | — |
| Completed | Open-label Extension to Protocol 1042-0600 NCT00512317 | Marinus Pharmaceuticals | Phase 2 |
| Completed | Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset S NCT00448916 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizure NCT00437281 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 1 / Phase 2 |
| Completed | An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in P NCT00991757 | SK Life Science, Inc. | Phase 3 |
| Completed | Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo NCT00351611 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Completed | Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Inte NCT00319501 | Pfizer | Phase 3 |
| Completed | A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy NCT00266604 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 |
| Completed | A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures NCT00280696 | UCB Japan Co. Ltd. | Phase 3 |
| Completed | An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Pa NCT00210522 | SK Life Science, Inc. | Phase 2 |
| Completed | Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizur NCT00151879 | UCB Pharma | Phase 2 / Phase 3 |
| Terminated | Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial S NCT00215215 | Cyberonics, Inc. | Phase 4 |
| Completed | An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy NCT00210652 | SK Life Science, Inc. | Phase 2 |
| Completed | Pilot Trial of a Behavioral Treatment for Epilepsy NCT00212745 | Oregon Health and Science University | Phase 1 / Phase 2 |
| Completed | MRI in Autosomal Dominant Partial Epilepsy With Auditory Features NCT00072813 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Completed | A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures NCT00643136 | Pfizer | Phase 3 |
| Completed | Pediatric Epilepsy Study NCT00050934 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Pregabalin Open-Label Extension Trial in Patients With Partial Seizures NCT00143143 | Pfizer | Phase 3 |
| Completed | A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed o NCT00231556 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients NCT00236886 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial- NCT00230698 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy NCT00236743 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy. NCT00236847 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With NCT00236873 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With NCT00236860 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With NCT00236691 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilep NCT00236730 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| No Longer Available | Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures NCT03559673 | UCB Biopharma S.P.R.L. | — |